Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in asian patients with schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 1889-1898

  Takahashi, Nagahide ^a   Takahashi, Masayoshi ^a   Saito, Takayuki ^b   Iizumi, Misuzu ^c   Saito, Yuki ^d   Shimizu, Hiroko ^d   Matsumura, Taka ^e  

^a Division of Clinical Science   (Japan)

^b Development Division   (Japan)

^c Trial Management Department   (Japan)

^d Division of Quantitative Sciences Department of Pathology   (Japan)

^e Janssen Pharmaceutical KK   (Japan)

Author keywords

Asian; Paliperidone palmitate; Positive and negative syndrome scale total score

Indexed keywords

PALIPERIDONE; PLACEBO;

ABDOMINAL DISCOMFORT; AKATHISIA; ANXIETY; ANXIETY DISORDER; APPLICATION SITE EXCORIATION; ARTICLE; ASIAN; BLOOD SAMPLING; BODY WEIGHT DISORDER; CATATONIC SCHIZOPHRENIA; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; ECZEMA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEADACHE; HEBEPHRENIA; HUMAN; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; INSOMNIA; JAPAN; KOREA; LIMIT OF QUANTITATION; LIVER DISEASE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; NAUSEA; OBESITY; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RELAPSE; RESIDUAL SCHIZOPHRENIA; RESTLESSNESS; RHINOPHARYNGITIS; SCHIZOPHRENIA; SEX DIFFERENCE; TAIWAN; TOOTH PAIN; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 84889580360     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S54051     Document Type: Article

References (21)

1. Clinical Challenges in Schizophrenia: A Six-Part Newsletter Series to Current Psychiatr. 2011;2:S1-S4. Available from: http://www.currentpsychiatry.com/home/article/challenges-and-opportunities-in-schizophrenia-treatment/f5fe98b0f0d1f5ae950fb84f07e42edc.html. Accessed November 4, 2013.
2. Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treatment. 2012;2012:407171.
3. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010;122:1-23.
4. Invega® Sustenna®. Prescribing information. Titusville, NJ: Janssen Pharmaceuticals Inc; 2012.
5. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13:635-647.
6. Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol. 2010;25:247-256.
7. Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology. 2010;35: 2072-2082.
8. Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:218-226.
9. Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30:235-244.
10. Banerjee A. Cross-cultural variance of schizophrenia in symptoms, diagnosis and treatment. Georgetown Undergraduate Journal of Health Sciences. 2012;6:18-24.
11. Coppola D, Liu Y, Gopal S, et al. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry. 2012;12:26.
12. Williams DR, Earl TR. Commentary: race and mental health - more questions than answers. Int J Epidemiol. 2007;36:758-760.
13. Li H, Rui Q, Ning X, Xu H, Gu N. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35: 1002-1008.
14. Inada T. Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to its Usage. Tokyo, Japan: Seiwa Shoten Publishers; 1996.
15. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266-1277.
16. Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011;25:685-697.
17. Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116:107-117.
18. Correll CU. Addressing barriers to using long-acting injectable antipsychotics and appropriately monitoring antipsychotic adverse effects. J Clin Psychiatry. 2013;74:e16.
19. Kapur S. 5-HT2 antagonism and EPS benefits: is there a causal connection? Psychopharmacology (Berl). 1996;124:35-39.
20. Nyberg S, Farde L, Halldin C, Dahl ML, Bertilsson L. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry. 1995;152:173-178.
21. Karlsson P, Dencker E, Nyberg S. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies. Clin Pharmacol Ther. 2006;79:P74.